JP2022514393A - ナチュラルキラー細胞に分化させるための培地および方法 - Google Patents
ナチュラルキラー細胞に分化させるための培地および方法 Download PDFInfo
- Publication number
- JP2022514393A JP2022514393A JP2021535699A JP2021535699A JP2022514393A JP 2022514393 A JP2022514393 A JP 2022514393A JP 2021535699 A JP2021535699 A JP 2021535699A JP 2021535699 A JP2021535699 A JP 2021535699A JP 2022514393 A JP2022514393 A JP 2022514393A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- population
- cell differentiation
- progenitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 300
- 238000000034 method Methods 0.000 title claims abstract description 52
- 210000000130 stem cell Anatomy 0.000 claims abstract description 209
- -1 pyridoindole compound Chemical class 0.000 claims abstract description 48
- 210000004027 cell Anatomy 0.000 claims description 196
- 239000002609 medium Substances 0.000 claims description 128
- 230000024245 cell differentiation Effects 0.000 claims description 104
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 81
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 81
- 210000002536 stromal cell Anatomy 0.000 claims description 41
- 210000004700 fetal blood Anatomy 0.000 claims description 21
- 239000011886 peripheral blood Substances 0.000 claims description 18
- 210000005259 peripheral blood Anatomy 0.000 claims description 18
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 18
- 239000007640 basal medium Substances 0.000 claims description 16
- 102000003812 Interleukin-15 Human genes 0.000 claims description 14
- 108090000172 Interleukin-15 Proteins 0.000 claims description 14
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 13
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 12
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims description 11
- 230000001472 cytotoxic effect Effects 0.000 claims description 11
- 239000002464 receptor antagonist Substances 0.000 claims description 11
- 229940044551 receptor antagonist Drugs 0.000 claims description 11
- 108010002586 Interleukin-7 Proteins 0.000 claims description 10
- 101710177504 Kit ligand Proteins 0.000 claims description 10
- 231100000433 cytotoxic Toxicity 0.000 claims description 10
- 108010002386 Interleukin-3 Proteins 0.000 claims description 9
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 8
- 239000003550 marker Substances 0.000 claims description 8
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 abstract description 44
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 79
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 79
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 72
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 65
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 65
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 60
- 150000001875 compounds Chemical class 0.000 description 58
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 52
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 52
- 238000005516 engineering process Methods 0.000 description 48
- 238000004519 manufacturing process Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 26
- 239000013589 supplement Substances 0.000 description 19
- 238000000576 coating method Methods 0.000 description 15
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 14
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 14
- 239000011248 coating agent Substances 0.000 description 12
- 230000003834 intracellular effect Effects 0.000 description 12
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000002243 precursor Substances 0.000 description 10
- DKVDSNMJXDQNCD-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinazoline Chemical class N1=CN=CC2=C(NC=C3)C3=CC=C21 DKVDSNMJXDQNCD-UHFFFAOYSA-N 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 8
- 102000000646 Interleukin-3 Human genes 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 108010074108 interleukin-21 Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000002698 KIR Receptors Human genes 0.000 description 7
- 108010043610 KIR Receptors Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 5
- 238000007427 paired t-test Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 4
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 4
- 239000012129 DRAQ7 reagent Substances 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 4
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 4
- 102100020880 Kit ligand Human genes 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 4
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 4
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 102100037362 Fibronectin Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 3
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 3
- 210000001939 mature NK cell Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- IVCGJOSPVGENCT-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinoline Chemical class N1=CC=CC2=C(NC=C3)C3=CC=C21 IVCGJOSPVGENCT-UHFFFAOYSA-N 0.000 description 1
- IEJAIKPHVAPFSS-UHFFFAOYSA-N 9h-pyrimido[4,5-b]indole Chemical compound N1C=NC=C2C3=CC=CC=C3N=C21 IEJAIKPHVAPFSS-UHFFFAOYSA-N 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100037917 CD109 antigen Human genes 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102100030024 Endothelial protein C receptor Human genes 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000738399 Homo sapiens CD109 antigen Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101001012038 Homo sapiens Endothelial protein C receptor Proteins 0.000 description 1
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102100032816 Integrin alpha-6 Human genes 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 102100039564 Leukosialin Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000376353 Stips Species 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 108010043603 integrin alpha4beta7 Proteins 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- AYYOZKHMSABVRP-UHFFFAOYSA-N methyl 1h-indole-6-carboxylate Chemical compound COC(=O)C1=CC=C2C=CNC2=C1 AYYOZKHMSABVRP-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本開示は、細胞の培養に関連し、かつより具体的には、免疫細胞様細胞(immune-like cell)の、または免疫系の細胞の培養に関連する。特に、本開示は、免疫細胞様細胞の、または免疫系の細胞の分化に関連する。
ナチュラルキラー(NK)細胞は、炎症誘発性(proinflammatory)サイトカインを分泌し、かつウイルスに感染した細胞および腫瘍細胞を溶解するというそれらの能力のために、感染および悪性病変に対する免疫において重要な役割を有するリンパ球である。NK細胞ベースのがん免疫療法は、成長中の分野である。同種ハプロ一致NK細胞は、移植片対宿主病(GVHD)を引き起こすことなく、白血病細胞に対して反応性である。「オフザシェルフ」の、キメラ抗原受容体(CAR)に関して遺伝子操作されたNK細胞は、自家CAR T細胞の望ましい代替物となり得る。
本開示は、分化したNK細胞を得るための、NK前駆細胞を分化させるための培地および方法に関連する。
培養下のNK前駆細胞の集団を提供する段階、ならびに
NK細胞を産生するのに十分な、量、濃度、および期間において、培養下のNK前駆細胞の集団を、上述のようなNK細胞分化培地に接触させる段階。
本開示は、NK前駆細胞を分化させるための培地および方法に関連し、かつ分化したNK細胞を得るための方法に関連する。
本開示の培地は、HSPCをNK細胞へと分化させるために使用され得る、またはNK前駆細胞の集団をNK細胞へと分化させるために使用され得る、いかなる培地も含む。NK細胞へのそのような分化とは、HSPCのNK細胞への分化を指し得、これは、それらの間のNK前駆細胞の、1種または複数種の集団の誘導を含み得る。または、NK細胞への分化とは、NK前駆細胞の集団をNK細胞へと直接的または間接的に分化させるものであり得る。
本開示の方法は、NK前駆細胞の集団からNK細胞を分化させるためのそのような段階を包含する。本開示の方法はまた、1種または複数種のNK前駆細胞中間集団を経る場合でも経ない場合でも、HSPCからNK細胞を分化させるためのそのような段階をも包含し得る。本明細書において開示される、NK細胞に分化させるための方法は、好ましくはインビトロ方法である。
ヒトCB試料はBloodworks NW(Seattle, WA)から入手し、そしてCD34+細胞は、EasySep(商標)ヒト臍帯血CD34ポジティブセレクションキットII(Human Cord Blood CD34 Positive Selection Kit II)(STEMCELL Technologies, カタログ番号17896)を用いて単離した。この方法で得られるCD34+細胞の純度は、典型的には90%超である。
NK細胞分化培地における、NK前駆細胞の2週間までの培養(すなわち、培養第14日~第28日)が、UM171もしくはUM729の存在下かまたはUM171もしくはUM729の非存在下で行われた点を除いて、実施例1に記載されるように細胞は培養された。
1 μM UM729の存在下で、実施例1および2に記載されるようにCD56+ NK細胞を分化させ、そして第28日に、既知のNK細胞マーカーの発現に関してフローサイトメトリーによって解析した。細胞を、示されるNK細胞マーカーに対する蛍光コンジュゲート抗体を用いて、15分間にわたり4℃で染色した。非特異的な結合は、FcRブロッカー、および5%のヒト血清またはラット血清を用いてブロックされた。死細胞は、光散乱プロファイル、および7-AAD染色またはDRAQ7染色によって除外した。調製された試料を、フローサイトメトリーによって解析した。
1 μM UM729の存在下で、実施例1および2に記載されるようにCD56+ NK細胞を分化させ、そして第28日に、既知のNK細胞マーカーの発現に関してフローサイトメトリーによって解析した。本実施例において記載されるマーカーに関して、本質的に実施例3に記載されるように細胞を染色した。KIR分子についての染色を、抗体の2種類のクローンの組み合わせを用いて実施し、ここで該抗体は180704およびHP-MA4であり、それぞれKIR分子の異なるサブセットを認識する。死細胞は、光散乱プロファイル、および7-AAD染色またはDRAQ7染色によって除外した。
ピリミドインドール化合物の存在下で、実施例1および2に記載されるようにCD56+ NK細胞を分化させ、そして第28日に、T細胞マーカーの発現に関してフローサイトメトリーによって解析した。解析された細胞は、CD3に関して、本質的に実施例3に記載されるように染色された。死細胞は、光散乱プロファイル、および7-AAD染色またはDRAQ7染色によって除外された。
1 μM UM729の存在下で、実施例1および2に記載されるようにCD56+ NK細胞を分化させ、そして第28日に、K562標的細胞に対するその細胞傷害性に関して解析した。
CD34+ CB細胞は、実施例1に記載されるように単離および培養された。CD34+ HSPCのNK細胞への分化に対するUM171の効果を調べるために、第0日~第14日の培地に100 nM UM171がさらに添加された点を除き、実施例1および2のように、第0日~第14日の培養と第14日~第28日の培養とで異なる培地が使用された。
実施例1に記載されるように、CD34+ CB細胞は単離され、そして第14日の時点まで培養された。14日間の培養後の、CB CD34+ HSPCに由来するNK前駆細胞は、マーカーであるCD5、CD7、およびCD56に対する抗体を用いて、本質的に実施例3に記載されるように染色された。BD FACSAria Fusion蛍光活性化セルソーターを用いて、CD56-細胞がゲーティングされ、そしてCD7+CD5-細胞、CD7+CD5+細胞、CD5-CD7-細胞がソートされた。
ピリミドインドール化合物以外の化合物が、たとえば芳香族炭化水素受容体(AhR)アンタゴニストなどが、培養下のHSPCを拡大させることが報告されている。そこで、NK前駆細胞の分化に対するAhRアンタゴニストの効果もまた試験された。
実施例1に記載されるように、CD34+ CB細胞は単離され、そして第14日の時点まで培養された。14日間の培養後の、CB CD34+ HSPCに由来するNK前駆細胞は、マーカーであるCD5、CD7、CD34、およびCD56に対する抗体を用いて、本質的に実施例3に記載されるように染色された。BD FACSAria Fusion蛍光活性化セルソーターを用いて、CD56-細胞がゲーティングされ、そしてCD34+CD7+CD5-およびCD34+CD7+CD5+、ならびにCD34-CD7+CD5-およびCD34-CD7+CD5+がソートされた。CD7-細胞は、陰性対照としてソートされた。
3種類の人工多能性幹細胞(iPSC)株 - WLS-1C、STiPSC M001、およびSTiPS F016 - 、ならびに1種類の胚性幹細胞(ESC)株 - H1 - が、mTeSR(商標)1中で維持された。PSCは採取され、そしてアキュターゼを用いて単一細胞懸濁液へと解離され、そして37 μmリバーシブルストレーナー(STEMCELL Technologies)を用いて濾過された。
PSC由来CD34+細胞は、実施例11に記載されるように産生させた。NK前駆細胞の集団の分化に対する、1μM UM729の存在または非存在の効果が評価された点を除いて、PSC由来CD34+細胞は、実施例11に記載されるように培養された。
Claims (29)
- ピリミドインドール化合物を含む、NK細胞分化培地。
- ピリミドインドール化合物がUM171またはUM729である、請求項1記載のNK細胞分化培地。
- 基礎培地をさらに含む、請求項1または2記載のNK細胞分化培地。
- SCF、FLT3L、IL-2、IL-3、IL-15、またはIL-7のうちの1つまたは複数をさらに含む、請求項3記載のNK細胞分化培地。
- 間質細胞または間質細胞代替物との接触による馴化を受けない、請求項1~4のいずれか一項記載のNK細胞分化培地。
- 芳香族炭化水素受容体アンタゴニストを含まない、請求項1~5のいずれか一項記載のNK細胞分化培地。
- 無血清である、請求項1~6のいずれか一項記載のNK細胞分化培地。
- NK前駆細胞を分化させる、請求項1~7のいずれか一項記載のNK細胞分化培地。
- NK前駆細胞が、一次試料から単離されるかまたは一次試料に由来する、請求項8記載のNK細胞分化培地。
- NK前駆細胞が多能性幹細胞に由来する、請求項8または9記載のNK細胞分化培地。
- 多能性幹細胞が人工多能性幹細胞(induced pluripotent stem cell)である、請求項10記載のNK細胞分化培地。
- NK細胞に分化させるための方法であって、
NK前駆細胞の集団を提供する段階、ならびに;
NK細胞を産生するのに十分な、濃度および期間において、培養下のNK前駆細胞の集団を、請求項1~11のいずれか一項記載の培地に接触させる段階
を含む、方法。 - NK前駆細胞の集団が、表現型マーカーに関して均一であるか、または表現型マーカーに関して不均一である、請求項12記載の方法。
- 表現型マーカーがCD7である、請求項13記載の方法。
- 表現型マーカーがCD5である、請求項13または14記載の方法。
- 接触させる段階の間に、NK細胞の出現頻度が増加する、請求項12~15のいずれか一項記載の方法。
- 接触させる段階の間に、NK細胞の数が増加する、請求項12~16のいずれか一項記載の方法。
- 接触させる段階の間に、NK前駆細胞の集団の出現頻度または数が増加または減少する、請求項12~17のいずれか一項記載の方法。
- 提供する段階および接触させる段階に、間質細胞も間質細胞代替物も存在しない、請求項12~18のいずれか一項記載の方法。
- 提供する段階および接触させる段階に、芳香族炭化水素受容体アンタゴニストが存在しない、請求項12~19のいずれか一項記載の方法。
- ピリミドインドール化合物の濃度が10 nM~3 μMである、請求項12~20のいずれか一項記載の方法。
- 前記期間が少なくとも1週間である、請求項12~21のいずれか一項記載の方法。
- 前記期間が約2週間である、請求項22記載の方法。
- NK細胞がCD56を発現する、請求項12~23のいずれか一項記載の方法。
- NK細胞が細胞傷害性である、請求項12~24のいずれか一項記載の方法。
- NK前駆細胞の集団が一次試料に由来する、請求項12~25のいずれか一項記載の方法。
- 細胞の集団が一次試料から単離される、請求項12~25のいずれか一項記載の方法。
- 一次試料が、臍帯血試料、骨髄試料、または末梢血試料である、請求項27記載の方法。
- 細胞の集団が、多能性幹細胞から分化する、請求項12~25のいずれか一項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783341P | 2018-12-21 | 2018-12-21 | |
US62/783,341 | 2018-12-21 | ||
PCT/CA2019/051875 WO2020124256A1 (en) | 2018-12-21 | 2019-12-20 | Media and methods for differentiating natural killer cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022514393A true JP2022514393A (ja) | 2022-02-10 |
JPWO2020124256A5 JPWO2020124256A5 (ja) | 2022-12-19 |
Family
ID=71102436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021535699A Pending JP2022514393A (ja) | 2018-12-21 | 2019-12-20 | ナチュラルキラー細胞に分化させるための培地および方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220056412A1 (ja) |
EP (1) | EP3898951A4 (ja) |
JP (1) | JP2022514393A (ja) |
KR (1) | KR20210114422A (ja) |
CN (1) | CN113383070A (ja) |
CA (1) | CA3124266A1 (ja) |
SG (1) | SG11202106565WA (ja) |
WO (1) | WO2020124256A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113337466B (zh) * | 2021-07-13 | 2023-03-24 | 杭州原生生物科技有限公司 | 一种无血清nk分化培养基及其制备方法 |
CN113789299B (zh) * | 2021-10-18 | 2023-03-24 | 新鲁细胞生物科技(海南)有限公司 | 一种脐血nk细胞的体外增殖培养基、体外培养试剂盒和体外培养方法 |
WO2023115049A1 (en) | 2021-12-17 | 2023-06-22 | Umoja Biopharma, Inc. | Cytotoxic innate lymphoid cell and uses thereof |
WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2812011T3 (pl) * | 2012-02-08 | 2020-06-29 | Glycostem Therapeutics B.V. | Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo |
EA201791443A1 (ru) * | 2014-12-31 | 2018-01-31 | Антродженезис Корпорейшн | Естественные киллерные клетки и их применения |
KR102278306B1 (ko) * | 2015-06-05 | 2021-07-15 | 헤마-퀘벡 | 조혈 줄기세포를 전구 세포로 배양 및/또는 분화시키는 방법 및 그의 용도 |
JP7049261B2 (ja) * | 2016-04-08 | 2022-04-06 | ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント | 幹細胞および/または前駆細胞からt前駆細胞を作製する方法ならびに該t前駆細胞の使用 |
-
2019
- 2019-12-20 CA CA3124266A patent/CA3124266A1/en active Pending
- 2019-12-20 CN CN201980090215.8A patent/CN113383070A/zh active Pending
- 2019-12-20 KR KR1020217022986A patent/KR20210114422A/ko unknown
- 2019-12-20 US US17/416,200 patent/US20220056412A1/en active Pending
- 2019-12-20 WO PCT/CA2019/051875 patent/WO2020124256A1/en unknown
- 2019-12-20 EP EP19900390.6A patent/EP3898951A4/en active Pending
- 2019-12-20 SG SG11202106565WA patent/SG11202106565WA/en unknown
- 2019-12-20 JP JP2021535699A patent/JP2022514393A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020124256A1 (en) | 2020-06-25 |
CA3124266A1 (en) | 2020-06-25 |
EP3898951A1 (en) | 2021-10-27 |
SG11202106565WA (en) | 2021-07-29 |
US20220056412A1 (en) | 2022-02-24 |
KR20210114422A (ko) | 2021-09-23 |
EP3898951A4 (en) | 2022-08-31 |
CN113383070A (zh) | 2021-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022514393A (ja) | ナチュラルキラー細胞に分化させるための培地および方法 | |
US20210395683A1 (en) | Methods of producing t memory stem cell populations | |
McGuckin et al. | Production of stem cells with embryonic characteristics from human umbilical cord blood | |
KR20180066263A (ko) | 조혈 세포 분화를 유도하기 위한 방법 및 조성물 | |
JP2000078968A (ja) | ヒト造血幹細胞 | |
McGuckin et al. | Potential for access to embryonic‐like cells from human umbilical cord blood | |
JP2022172252A (ja) | 造血移植片の改善方法 | |
US20160151421A1 (en) | Methods and compositions for long term hematopoietic repopulation | |
Bosio et al. | Isolation and enrichment of stem cells | |
US20230257707A1 (en) | Systems and methods for differentiating hematopoietic cells | |
EP1877541A2 (en) | Method of obtaining a population of human haemopoietic stem cells | |
WO1995003693A1 (en) | Novel stem cell marker | |
KR20240005792A (ko) | B 계통 세포의 분화 및 확장을 위한 조성물 및 방법 | |
US20240150713A1 (en) | Method for Producing Human Chimeric Antigen Receptor T-Cell Population Enriched with Stem Cell-like Memory T-Cells | |
O'Brien | Induced Human Pluripotent Stem Cell–derived NK Cells as an Alternative Source of Lymphocytes for Anti-Cancer Immunotherapy | |
US20080112933A1 (en) | Methods and Compositions for Increasing Stem Cell Homing Using Gas Activators | |
CA3213581A1 (en) | Generating t cell precursors via agonizing tumor necrosis factor receptor 2 | |
JP2024068112A (ja) | 幹細胞様メモリーt細胞を高濃度に含有するヒトキメラ抗原受容体t細胞集団の作製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240307 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240329 |